Morgan Stanley’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $105K | Buy |
9,178
+9
| +0.1% | +$72 | ﹤0.01% | 6230 |
|
|
2026
Q1 | $43.4K | Sell |
9,169
-6,822
| -43% | -$41.6K | ﹤0.01% | 6472 |
|
|
2025
Q4 | $289K | Sell |
15,991
-19,947
| -56% | -$298K | ﹤0.01% | 5771 |
|
|
2025
Q3 | $515K | Buy |
35,938
+21,012
| +141% | +$242K | ﹤0.01% | 5488 |
|
|
2025
Q2 | $115K | Buy |
14,926
+3,098
| +26% | +$22.6K | ﹤0.01% | 6081 |
|
|
2025
Q1 | $70.3K | Sell |
11,828
-16,523
| -58% | -$144K | ﹤0.01% | 6160 |
|
|
2024
Q4 | $377K | Buy |
28,351
+12,162
| +75% | +$128K | ﹤0.01% | 5542 |
|
|
2024
Q3 | $132K | Buy |
16,189
+6,404
| +65% | +$54.8K | ﹤0.01% | 5890 |
|
|
2024
Q2 | $83.2K | Sell |
9,785
-44,060
| -82% | -$663K | ﹤0.01% | 6025 |
|
|
2024
Q1 | $934K | Sell |
53,845
-89,625
| -62% | -$1.59M | ﹤0.01% | 4984 |
|
|
2023
Q4 | $1.84M | Buy |
143,470
+54,883
| +62% | +$1.28M | ﹤0.01% | 4968 |
|
|
2023
Q3 | $3.28M | Sell |
88,587
-11,524
| -12% | -$513K | ﹤0.01% | 4042 |
|
|
2023
Q2 | $4.03M | Sell |
100,111
-17,778
| -15% | -$1.01M | ﹤0.01% | 3935 |
|
|
2023
Q1 | $8.55M | Buy |
117,889
+10,299
| +10% | +$999K | ﹤0.01% | 3279 |
|
|
2022
Q4 | $8.82M | Sell |
107,590
-10,367
| -9% | -$1.08M | ﹤0.01% | 3203 |
|
|
2022
Q3 | $11.1M | Sell |
117,957
-10,998
| -9% | -$1.24M | ﹤0.01% | 2841 |
|
|
2022
Q2 | $25.1M | Buy |
128,955
+7,374
| +6% | +$1.2M | ﹤0.01% | 2034 |
|
|
2022
Q1 | $28.2M | Buy |
121,581
+19,859
| +20% | +$6.32M | ﹤0.01% | 1765 |
|
|
2021
Q4 | $40.1M | Sell |
101,722
-10,668
| -9% | -$4.49M | ﹤0.01% | 1509 |
|
|
2021
Q3 | $50.3M | Sell |
112,390
-9,040
| -7% | -$3.24M | 0.01% | 1287 |
|
|
2021
Q2 | $47.2M | Sell |
121,430
-5,879
| -5% | -$2.1M | 0.01% | 1350 |
|
|
2021
Q1 | $45.7M | Sell |
127,309
-17,689
| -12% | -$7.82M | 0.01% | 1231 |
|
|
2020
Q4 | $71.2M | Buy |
144,998
+92,600
| +177% | +$42.7M | 0.01% | 885 |
|
|
2020
Q3 | $17M | Buy |
52,398
+21,297
| +68% | +$7.25M | ﹤0.01% | 1599 |
|
|
2020
Q2 | $11.3M | Sell |
31,101
-107,392
| -78% | -$27.1M | ﹤0.01% | 1862 |
|
|
2020
Q1 | $29.5M | Buy |
138,493
+21,179
| +18% | +$6.72M | 0.01% | 1027 |
|
|
2019
Q4 | $48.3M | Sell |
117,314
-830
| -0.7% | -$286K | 0.01% | 955 |
|
|
2019
Q3 | $41.7M | Buy |
118,144
+38,242
| +48% | +$14.3M | 0.01% | 964 |
|
|
2019
Q2 | $40.2M | Buy |
79,902
+28,604
| +56% | +$20.2M | 0.01% | 968 |
|
|
2019
Q1 | $51M | Sell |
51,298
-21,928
| -30% | -$20.4M | 0.01% | 822 |
|
|
2018
Q4 | $63.6M | Sell |
73,226
-2,379
| -3% | -$2.21M | 0.02% | 707 |
|
|
2018
Q3 | $78.2M | Sell |
75,605
-6,073
| -7% | -$5.94M | 0.02% | 720 |
|
|
2018
Q2 | $75M | Sell |
81,678
-4,677
| -5% | -$5.02M | 0.02% | 714 |
|
|
2018
Q1 | $84.2M | Buy |
86,355
+16,883
| +24% | +$15.4M | 0.02% | 662 |
|
|
2017
Q4 | $31.4M | Buy |
69,472
+11,966
| +21% | +$4.42M | 0.01% | 1301 |
|
|
2017
Q3 | $23.8M | Buy |
57,506
+18,044
| +46% | +$6.8M | 0.01% | 1437 |
|
|
2017
Q2 | $13.8M | Buy |
39,462
+32,460
| +464% | +$12.5M | ﹤0.01% | 1853 |
|
|
2017
Q1 | $3.6M | Buy |
7,002
+4,174
| +148% | +$1.73M | ﹤0.01% | 3221 |
|
|
2016
Q4 | $1M | Buy |
2,828
+2,521
| +821% | +$1.07M | ﹤0.01% | 4459 |
|
|
2016
Q3 | $164K | Buy |
307
+156
| +103% | +$84.7K | ﹤0.01% | 5097 |
|
|
2016
Q2 | $85K | Sell |
151
-85
| -36% | -$40.8K | ﹤0.01% | 5310 |
|
|
2016
Q1 | $112K | Sell |
236
-4,802
| -95% | -$2.16M | ﹤0.01% | 5265 |
|
|
2015
Q4 | $3.33M | Buy |
5,038
+4,265
| +552% | +$3.23M | ﹤0.01% | 3051 |
|
|
2015
Q3 | $608K | Buy |
773
+532
| +221% | +$649K | ﹤0.01% | 4485 |
|
|
2015
Q2 | $318K | Buy |
241
+237
| +5,925% | +$272K | ﹤0.01% | 4983 |
|
|
2015
Q1 | $4K | Sell |
4
-27
| -87% | -$17.8K | ﹤0.01% | 6361 |
|
|
2014
Q4 | $20K | Buy |
+31
| New | +$18.9K | ﹤0.01% | 6046 |
|
Other funds holding ATRA
VCM
SCA
VFT
Morgan Stanley's ATRA Position: Q2 2026 in Review
Morgan Stanley increased its Atara Biotherapeutics (ATRA) stake by 0.1% in Q2 2026, buying an estimated $72 and bringing the position to 9,178 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #6230.
Morgan Stanley first reported a position in ATRA in Q4 2014 and has held it in 47 quarters since. The position peaked at $84.2M in Q1 2018. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.
- Morgan Stanley held 9,178 shares of Atara Biotherapeutics worth $105K as of Q2 2026.
- Morgan Stanley bought 9 Atara Biotherapeutics shares in Q2 2026, an estimated $72.
- Atara Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6230 holding.
- Morgan Stanley first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 47 quarters since.
- Morgan Stanley's Atara Biotherapeutics position peaked at $84.2M in Q1 2018.
- 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.